PAF-Binding and Endothelins Activity

作者: Olga Tiniakova , Liomar A. A. Neves , Michael Gralinski

DOI:

关键词: InflammationEndothelinsArachidonic acidPharmacologyRespiratory functionReceptorPlateletChemistryAngiogenesisVascular permeability

摘要: Principle and Rationale Injection of platelet-activating factor (PAF) induces a wide range potent specific effects on target cells, including aggregation platelets shock symptoms like systemic hypotension, pulmonary hypertension, increased vascular permeability, neutropenia, thrombocytopenia. Inhalation PAF causes immediate bronchoconstriction followed by inflammation the airways (for further information, see section “Effect Arachidonic Acid or Respiratory Function In Vivo,” chapter “▶Respiratory Activity”). Hikiji et al. (2004) showed in PAF-deficient mice that absence receptor protects from osteoporosis following ovariectomy, model postmenopausal osteoporosis. is also implicated estrogen-induced angiogenesis via nuclear factor-kB activation (Seo 2004) delaying corneal wound healing (Bazan 2005). The belongs to superfamily G protein-coupled receptors (Chao Olson 1993; Izumi Shimizu 1995). Cloning studies have indicated single human gene containing an intron at 50 flanking region, providing alternative sequences (Ishii 2000). antagonists been reviewed extensively Koltai (1994) Summers Albert (1995). procedure used detect compounds inhibit binding H-PAF (plateletactivating factor) rabbit (PAF receptor).

参考文章(143)
Hitoshi Miyazaki, Motohiro Kondoh, Yasushi Masuda, Hirotoshi Watanabe, Kazuo Murakami, Endothelin Receptors and Receptor Subtypes Springer, New York, NY. pp. 58- 71 ,(1992) , 10.1007/978-1-4614-7514-9_5
Tommy A. Brock, N. Raju Danthuluri, Cellular Actions of Endothelin in Vascular Smooth Muscle Springer, New York, NY. pp. 103- 124 ,(1992) , 10.1007/978-1-4614-7514-9_7
Yoshihiro Urade, Yasushi Fujitani, Kyoko Oda, Tadashi Watakabe, Ichiro Umemura, Michihiro Takai, Toshikazu Okada, Kiyoshi Sakata, Hideaki Karaki, Retraction concerning an endothelin B receptor-selective antagonist: Urade, Y., Fujitani, Y., Oda, K., Watakabe, T., Umemura, L., Takai, M., Okada, T., Sakata, K. and Karaki, H. (1992) FEBS Lett. 311, 12-16 FEBS Letters. ,vol. 342, pp. 103- 103 ,(1994) , 10.1016/0014-5793(94)80593-8
K Ohnaka, R Takayanagi, M Nishikawa, M Haji, H Nawata, Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. OFF. Journal of Biological Chemistry. ,vol. 268, pp. 26759- 26766 ,(1993) , 10.1016/S0021-9258(19)74378-6
M Takahashi, Y Matsushita, Y Iijima, K Tanzawa, Purification and characterization of endothelin-converting enzyme from rat lung. Journal of Biological Chemistry. ,vol. 268, pp. 21394- 21398 ,(1993) , 10.1016/S0021-9258(19)36936-4
M Takahashi, K Shimada, K Tanzawa, Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. Journal of Biological Chemistry. ,vol. 269, pp. 18275- 18278 ,(1994) , 10.1016/S0021-9258(17)32298-6
James B. Summers, Daniel H. Albert, Platelet activating factor antagonists Advances in pharmacology. ,vol. 32, pp. 67- 168 ,(1992) , 10.1016/S1054-3589(08)61012-1
Terry J. Opgenorth, Jinshyun R. Wu‐Wong, Kazumi Shiosaki, Endothelin-converting enzymes. The FASEB Journal. ,vol. 6, pp. 2653- 2659 ,(1992) , 10.1096/FASEBJ.6.9.1612289
Terry J. Opgenorth, Endothelin Receptor Antagonism Advances in pharmacology (San Diego). ,vol. 33, pp. 1- 65 ,(1995) , 10.1016/S1054-3589(08)60665-1